دورية أكاديمية
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases.
| العنوان: | Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases. |
|---|---|
| المؤلفون: | LaCava AF; Department of Allergy and Clinical Immunology, Cleveland Clinic, 224 W. Exchange Street, Suite 380, Akron, OH, 44302, USA. anthonylacavajr@gmail.com., Fadugba OO; Division of Pulmonary, Allergy, & Critical Care Medicine, Section of Allergy & Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. |
| المصدر: | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology [Allergy Asthma Clin Immunol] 2023 Aug 29; Vol. 19 (1), pp. 78. Date of Electronic Publication: 2023 Aug 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Country of Publication: England NLM ID: 101244313 Publication Model: Electronic Cited Medium: Print ISSN: 1710-1484 (Print) Linking ISSN: 17101484 NLM ISO Abbreviation: Allergy Asthma Clin Immunol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: Oct. 2009- : London : BioMed Central Original Publication: Hamilton, Ont. : BC Decker, c2004- |
| مستخلص: | Background: While both the AAAAI/ACAAI and the EAACI/GA 2 LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinicians are hesitant to initiate cyclosporine due to paucity of clinical data. The objective of this study was to report real-life clinical outcomes in adult patients with chronic urticaria who had an inadequate response to omalizumab and were switched from omalizumab to cyclosporine. Medical records of adult patients with chronic urticaria who had an inadequate response with omalizumab and were later treated with cyclosporine were reviewed retrospectively. Data pertaining to treatment method, clinical response, and adverse effects were recorded. Results/presentation of Cases: Five patients with omalizumab-refractory chronic urticaria, three of whom also had angioedema and one with an inducible urticaria, were treated with low doses of oral cyclosporine (1-3 mg/kg/d). Four of five patients in this case series had complete resolution of symptoms with oral cyclosporine, while continuing other standard therapies. Systemic side effects occurred in three patients which prompted drug discontinuation in two patients. Discussion: Cyclosporine alone was effective in inducing urticaria control in adult patients with chronic urticaria who had an inadequate response to omalizumab, though the impact of cyclosporine was limited by reversible adverse effects. Adverse effects were associated with pre-existing medical conditions. As novel chronic urticaria therapies are being investigated, this experience highlights the importance of uncovering chronic urticaria subtypes which tend to respond to cyclosporine, while providing alternative treatments with better tolerability. (© 2023. Canadian Society of Allergy & Clinical Immunology.) |
| References: | Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticarial A GA2LEN task force report1. Allergy. 2010;66(3):317–30. (PMID: 10.1111/j.1398-9995.2010.02496.x21083565) Alen Coutinho I, Regateiro FS, Fernandes RA, Pita JS, Gomes R, Coelho C, et al. Refractory chronic urticaria in adults: clinical characterization and predictors of severity. Allergy Asthma Clin Immunol. 2020. https://doi.org/10.1186/s13223-020-00496-0 . (PMID: 10.1186/s13223-020-00496-0332924537661155) Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA 2 LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021;77(3):734. (PMID: 10.1111/all.1509034536239) Zhao Z-T, Ji C-M, Yu W-J, Meng L, Hawro T, Wei J-F, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750.e4. (PMID: 10.1016/j.jaci.2015.12.134227040372) Casale TB, Bernstein JA, Maurer M, Saini SS, Trzaskoma B, Chen H, et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3(5):743-750.e1. (PMID: 10.1016/j.jaip.2015.04.01526054553) Trojan TD, Khan DA. Calcineurin inhibitors in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):412–20. (PMID: 10.1097/ACI.0b013e32835571f622729026) Kulthanan K, Chaweekulrat P, Komoltri C, Hunnangkul S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586–99. (PMID: 10.1016/j.jaip.2017.07.01728916431) Rosenblum JD, Nassau S, Fonacier L, Mawhirt SL. Concomitant treatment with omalizumab and cyclosporine for chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2020;125(1):111–2. (PMID: 10.1016/j.anai.2020.04.02032360694) Sánchez J, Alvarez L, Cardona R. Cyclosporine and omalizumab together: a new option for chronic refractory urticaria. J Allergy Clin Immunol Pract. 2020;8(6):2101–3. (PMID: 10.1016/j.jaip.2020.02.01232112923) Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–7. (PMID: 10.1016/j.jaci.2014.02.03624766875) Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-1372.e6. (PMID: 10.1016/j.jaci.2013.12.107624522090) Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965–81. https://doi.org/10.1111/all.14757 . (PMID: 10.1111/all.1475733539587) Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–24. (PMID: 10.1016/j.jaip.2019.07.02131374358) Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. https://doi.org/10.1038/s41572-022-00389-z . (PMID: 10.1038/s41572-022-00389-z36109590) Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria when and which. J Allergy Clin Immunol Pract. 2021;9(3):1067–78. https://doi.org/10.1016/j.jaip.2020.11.043 . (PMID: 10.1016/j.jaip.2020.11.04333685605) |
| فهرسة مساهمة: | Keywords: Chronic spontaneous urticaria; Cyclosporine; Omalizumab; Refractory urticaria |
| تواريخ الأحداث: | Date Created: 20230829 Latest Revision: 20231118 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10466821 |
| DOI: | 10.1186/s13223-023-00820-4 |
| PMID: | 37644553 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1710-1484 |
|---|---|
| DOI: | 10.1186/s13223-023-00820-4 |